Open-label, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients With High Risk Diffuse Large B Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms Borma
- 04 Sep 2018 Planned End Date changed from 1 Dec 2018 to 30 Oct 2018.
- 04 Sep 2018 Planned primary completion date changed from 1 Dec 2017 to 30 Oct 2018.
- 25 Oct 2013 New trial record